3:02 PM
 | 
Nov 10, 2017
 |  BioCentury  |  Finance

Vaccine dream team

Why investors flocked to a €42 million series B for cancer vaccine play Nouscom

An experienced vaccine development team, vector technology that has been tested in humans and two neoantigen programs poised to enter the clinic helped Nouscom AG land a €42 million ($48.8 million) series B round.

Abingworth led the tranched round, which closed on Nov. 6, and was joined by fellow new investor 5AM Ventures and existing investors LSP and Versant Ventures. Details of the tranches are undisclosed.

Five members of Nouscom’s executive team hail from infectious disease vaccine company Okairos AG, which GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) acquired in 2013 for...

Read the full 426 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >